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Abstract
Purpose: The purpose of this study was to evaluate the role of post-treatmentPositron Emission Tomography/Computed Tomography (PET/CT) in aggressivenon-Hodgkin’s lymphoma (NHL) with regard to the clinical and treatmentcharacteristics and disease-free survival (DFS). Methods: We retrospectivelystudied charts of 30 patients with aggressive NHL who had PET/CT only aftercompletion of treatment. Results: Thirty patients received CHOP(cyclophosphamide, doxorubicin, vincristine, and prednisone) or Rituximab(R)-CHOP (22 and 8 patients respectively), followed by radiotherapy in 19/30patients (63.3%). Following 3-4 cycles of chemotherapy, interim CT showedregressive, stationary and progressive disease in 18, 10, 2 (60%, 33.3%, 2%)patients respectively. PET/CT was performed 4-6 weeks after end of treatment.22/30 (73.3%) patients had negative scan, of whom 13 (59.1%) patients remainedin remission till the end of the study while 9 patients relapsed after a median DFSof 12 months. PET/CT was positive in 8/30 (26.7%) patients who had refractorydisease. PET/ CT scan had sensitivity of 75%, specificity of 72.7%, negativepredictive value (NPV) of 88.9%, and positive predictive value (PPV) of 50%.
Conclusion: PET/CT has an important role in end- of- therapy response evaluationin fluorodeoxyglucose (FDG)-avid aggressive NHL. It proves high sensitivity andspecificity in detection of residual disease and provides an accurate indication ofoverall survival and disease-free survival. CT continues to have an important rolein post-treatment response assessment whether as a single modality or incombination with PET scan.
Keywords: Aggressive NHL, Post-therapy, PET/CT, Disease-free survival.
1. IntroductionDespite the increasing annual incidence of NHL, theoverall 5-year survival (ORS) rate is steadily improving.This is partly due to advances in treatment regimenswhich achieve remission rates with less patient toxicity.1In adults the most common subtypes of NHL arefollicular lymphoma (FL) and diffuse large B-celllymphoma (DLBCL), which account for more than 50%of NHL.2,3 Histologically NHL is classified into indolent,aggressive, and highly aggressive subtypes. Prognosis
and treatment options of NHL depend on the diseasestage, grade, and the histologic subtype.DLBCL is the most common subtype of NHL accountingfor 30 - 35% % of all newly diagnosed cases and morethan 80% of aggressive NHL4, followed by mantle celllymphoma (MCL) and adult T-cell leukemia/lymphomawhich represent about 6 and 8% of NHL respectively.5DLBCL has a heterogeneous outcome where almost halfof the patients are incurable due to poor response to
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treatment and die because of the disease.6 Many patientswith DLBCL initially respond to R-CHOP (rituximab pluscyclophosphamide, doxorubicin, vincristine, andprednisone), however the 5-year overall survival ratesfor these patients range from 45% to 82% due to theheterogeneous nature of this disease.7The combined use of PET and CT has higher sensitivityand specificity due to the combined benefit of anatomicand functional imaging in the initial staging, restaging,and assessment of response to therapy in hematologicmalignancies as compared to FDG-PET and CT alone.Aggressive NHL such as DLBCL, grade III FLs, MCL havemoderate to high F-FDG uptake with a sensitivity of85-100%.8 PET/CT is considered a standard imagingmodality in B-cell aggressive NHL which can accuratelydiagnose, assess the treatment response, and estimatethe prognosis.9,10 End-of-treatment PET/CT is used toevaluate the efficacy of treatment, to follow-up residualtumor, and to select treatment.9,11 The follow-up PET/CTin NHL has 90% sensitivity and 88% specificity. Apositive PET/CT scan at the end of treatment is a strongindicator of poor survival where the risk for diseaserelapse increases.12 This residual positivity has beenincorporated into revised response criteria foraggressive lymphoma.13 Patients with negativepost-treatment scan have excellent prognosis.12Spaepen et al.14 showed that 56 of 67 NHL patients hadnegative scans after end of first line treatment, andremained in complete remission at a median follow-upduration of 653 days whereas the 26 patients who had apositive scan developed relapse at a median of 73 days.According to the authors the PET scan ability to identifya residual aggressive disease after completion of the firstline chemotherapy had a NPV of 80% and a PPV of100%. Similarly studies involving more than 300patients diagnosed with aggressive NHL, reportedconsistently high NPV 80% to 100% and a lower PPV of50% to 100%.15-19 PET/CT is currently recommended inDLBCL to improve the accuracy of staging and end oftreatment evaluation.20 Recently clinical trials focus onthe prognostic role of early interim PET/CT after fewcycles of chemotherapy to guide response-adaptedtreatment.21 A meta-analysis by Terasawa et al.22,demonstrated that PET/CT had a sensitivity of 81% anda specificity of 97% for advanced-stage Hodgkin’slymphoma (HL), and a sensitivity of 78% and aspecificity of 87% for DLBCL. More recent studies inDLBCL reported good NPV versus more variable PPV.9,21The role of interim PET/CT in aggressive NHL remainsunclear compared to HL where some studies reportbetter overall survival and disease free survivalassociated with a negative interim PET/CT, while otherstudies have not confirmed these results partly due tothe variety of interpretation criteria used.15,23,24 Inadvanced FL, post-treatment PET seems to betterpredict outcome than interim PET.25 Interim PET/CT
should not be used to guide treatment and isrecommended in the setting of clinical trials.20To standardize the PET/CT interpretation criteria forlymphoma between different centers the InternationalHarmonization Project (IHP) criteria were developedwhere the mediastinal blood pool uptake was used as areference background to define positive PET/CT bydetecting a residual mass 2 cm or more.26 The IHPcriteria which are incorporated into the StandardResponse Criteria20 are commonly used in evaluation ofend-of-treatment PET scans. The Deauville criteriafurther improved the interpretation criteria of PET/CTscans by using a five-point scale to assess the FDGuptake in the involved site relative to that of themediastinum and the liver.27 This scale is agreeable andincreasingly used for interpreting therapy response inDLCBL and FL.28,25,29 The five-point scale has beenincorporated into the updated standard responsecriteria for lymphoma (The Lugano Classification).30Standardized uptake value (SUV) is a third approachwhich has been adopted as an interpretation criteria tohelp reduce false-positivity of interim PET/CT and toimprove prognostic value in NHL. It is a semiquantification of FDG uptake using the maximum SUV(SUV max) at baseline and midtherapy. Otherquantitative variables for response evaluation understudy include the change in maximum SUV (ΔSUV max),ΔSUV mean, total lesion glycolysis, and metabolic tumorvolume.31In this study we aimed to evaluate the role ofpost-treatment PET/CT in aggressive NHL with regardto the clinical and treatment characteristics and DFS.
2. Methods and MaterialsBetween January 2012 and December 2014 weretrospectively reviewed the charts of pathologicallyproven aggressive NHL patients treated at NasserInstitute for Research and Cancer Treatment and at thedepartment of Clinical Oncology, Ain-Shams University.The charts were examined after obtaining the approvalof the Research Ethical Committee, Faculty of Medicine,Ain-Shams University.Thirty patients fulfilled the inclusion criteria whichincluded both sexes, age from 18-65 years old, EasternCooperative Oncology Group (ECOG) performance statusof 0-2, newly diagnosed and previously treated patientswith biopsy proven diagnosis of aggressive NHL. Stagingof lymphoma was done according to the Ann Arborstaging system (National Comprehensive Cancernetwork (NCCN) 2011).32 Risk factor evaluation wasdone using the International NHL Prognostic FactorsProject (IPI).33 All the patients had interim CT whichshowed evidence of disease.
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First line treatment consisted of 6-8 cycles of CHOP orRituximab (R) plus CHOP and/or radiotherapy.Complete patient history and relative examination datawere collected at each visit. Only end-of- treatmentPET/CT was performed, no pre-treatment or interimPET/CT was done due to the financial costs.
2.1 Statistical AnalysisData were analyzed using the Statistical Package forSocial Science (IBM SPSS) version 20 for Windows(SPSS, Chicago, IL, USA). Disease-free survival wasdefined as the interval from the date of remission to thedate of disease progression or first relapse. Thecorrelation of post- therapy negative and positivePET/CT residual masses with the different patient andtreatment characteristics was analyzed using Chi-squaretest. Kaplan–Meier test and Log-rank test were used toanalyze the correlation of DFS with negative andpositive PET/CT scans. The comparison betweenpatients with negative and positive PET/CT scansregarding quantitative data was done using theIndependent t-test. P value of < 0.05 was considered tobe statistically significant.
3. ResultsThirty patients fulfilled the eligibility criteria and theircharacteristics are summarized in (Table 1). The ageranged from 30-86 years with a slight femalepredominance (18/30, 53.3%). Following completion oftherapy, response was evaluated by PET/CT imagingwhich was negative in 22/30 (73.3%) and positive in8/30 patients (26.7%). As regards performance status,16/22 (72.7%) patients with negative PET/CT scan hadan ECOG 1, compared to ECOG 2 in 5/8 (62.5%) ofpatients with positive PET/CT imaging (p 0.024).Associated comorbidities mainly hypertension anddiabetes mellitus were more common in patients who
had positive post-therapy PET/CT scan (75%) than inpatients with negative PET/CT scans (27.3%) (p 0.018).The majority of the patients had stage II and III disease63.7% and 75% respectively (p 0.615). DLBCL was themost common histologic subtype 93.3%. Most of thepatients with negative post-therapy PET/CT scan hadintermediate and high risk IPI (45.5% each), while62.5% of patients with positive PET/CT scan hadintermediate risk IPI (p 0.6). The studied cohort wastreated with CHOP as first line treatment (73.3%) andreceived no radiotherapy in (63.3%) of patients.Following 3-4 cycles of chemotherapy, interim CT scanshowed regressive disease in 16/30 (72.7%) of patientswho later had negative post-therapy PET/CT scans,while interim CT showed regressive disease in 2/30(25%) of patients who had a positive PET/CT scan bythe end of treatment. By the end of therapy, responseassessment was performed by PET/CT scan which wasnegative in (22/30, 73.3%) and positive in 8/30 ofpatients. Remission was achieved in 59.1% and 40.9% ofpatients who had negative PET/CT relapsed, whereas100% of patients with positive PET/CT scan hadrefractory disease (p 0.000) (Table 2, 3).The effect of clinical and treatment factors on the resultof post-treatment PET/CT was studied (Table 4). Nodaldisease was the most common disease site in bothpositive and negative PET/CT scans (59.1%, 75%)respectively. 16/22 (72.7%) of PET negative patientsand 6/8 (75%) of PET positive patients received CHOPchemotherapy (p 0.9). A significant correlation betweensome of the clinical factors and result of the end-oftreatment PET/CT was detected namely sex (p 0.024),ECOG status (p 0.024) and associated comorbidities (p0.018).
Table 1: Clinical characteristics Variable Total no. 30Sex Male 14 (46.7%)Female 16 (53.3%)Age Mean ± SD 48.47 ± 10.90Range 30 – 86
ECOG PS 0 3 (10%)1 19 (63.3%)2 8 (26.7%)Comorbidities No 18 (60.0%)Yes 12 (40.0%)
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Subtype DLBC 28 (93.3%)Follicular 1 (3.3%)T- cell 1 (3.3%)
Stage 1 4 (13.3%)2 9 (30.0%)3 11 (36.7%)4 6 (20.0%)
Site of disease Nodal 19 (63.3%)Extra-nodal 8 (26.7%)Spleen 3 (10.0%)A/B No symptoms 27 (90.0%)Positive symptoms 3 (10.0%)LDH Mean±SDRange 376.23 ± 87.79198 – 570Hemoglobin Mean±SDRange 11.42 ± 1.258.6 – 14.1Leukocytosis Mean±SDRange 9.84 ± 5.994.3 – 18.9
IPI Low 3 (10.0%)Low-Intermediate 15 (50.0%)Intermediate-High 12 (40.0%)PS: performance status, SD: standard deviation, LDH: lactate dehydrogenase enzyme, IPI: international prognostic index
Table 2: Primary Treatment CharacteristicsVariable Table no. 30Chemotherapy CHOPR-CHOP 22 (73.3%)8 (26.7%)
Number of cycles Mean ± SDRange 6.47 ± 0.866-8
Radiotherapy NOYes 19 (63.3%)11 (36.7%)
Interim CT (after 3-4 cycles)
Complete responseRegressiveStationaryProgressive
2 (0.6%)16 (53.3%)10 (33.3%)2 (0.6%)
End-of- treatment PET/ CT NegativePositive 22 (73.3%)8 (26.7%)Response RemissionRelapseRefractory 13 (43.3%)9 (30%)8 (26.7%)
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Table 3: Result of PET/CT scan at end-of-treatment
End-of-treatment PET Negative PET Positive PET Chi-square testNo. % No. % X² P-value
Response Remission 13 59.1% 0 0% 20.649 0.000Relapsed 9 40.9% 0 0%Refractory 0 0.0% 8 100%
Table 4: Relation between clinical data and end-of-treatment PET/CT scanPost therapy PET/CT Negative PET Positive PET Chi-square testNo = 22 No = 8 X²/t* P-valueSex Male 13 (59.1%) 1 (12.5%) 5.117 0.024Female 9 (40.9%) 7 (87.5%)Age Mean ± SD 49.45 ± 11.49 45.75 ± 9.19 -0.819 0.420Range 30 – 86 36 – 58
ECOG PS 0 3 (13.6%) 0.0%1 16 (72.7%) 3 (37.5%) 1.212 0.0242 3 (13.6%) 5 (62.5%)Comorbidities No 16 (72.7%) 2 (25.0%) 5.568 0.018Yes 6 (27.3%) 6 (75.0%)
Subtype DLBC 20 (90.9%) 8 (100.0%) 0.779 0.677Follicular 1 (4.5%) 0 (0.0%)T-cell 1 (4.5%) 0 (0.0%)
Stage 1 4 (18.2%) 0 (0.0%) 1.798 0.6152 6 (27.3%) 3 (37.5%)3 8 (36.4%) 3 (37.5%)4 4 (18.2%) 2 (25.0%)
Site of disease Nodal 13 (59.1%) 6 (75.0%) 1.337 0.513Extra-nodal 6 (27.3%) 2 (25.0%)Spleen 3 (13.6%) 0 (0.0%)A/B No symptoms 20 (90.9%) 7 (87.5%) 0.076 0.783Positive symptoms 2 (9.1%) 1 (12.5%)
IPI Low 2 (9.1%) 1 (12.5%) 1.023 0.600Low-Intermediate 10 (45.5%) 5 (62.5%)Intermediate-High 10 (45.5%) 2 (25.0%)
* Independent t-test P > 0.05 NS, P < 0.05: S, P < 0.01: HS
Chemotherapy was associated with negative PET/CT (p ≥ 0.05). 9/22 patients who received radiotherapy had negativePET/CT (p ≥ 0.05). Interim CT was the only treatment-related factor that significantly affected the result ofpost-therapy PET/CT (p 0.013) (Table 5).
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Table 5: Relation between type of treatment and end-of-treatment PET/CT
End-of-treatment PET/CT Negative PET Positive PET Chi-square testNo = 22 No = 8 X²/t* P-value
Chemotherapy CHOP 16 (72.7%) 6 (75.0%) 0.015 0.901R-CHOP 6 (27.3%) 2 (25.0%)
Number ofcycles Mean ± SD 6.45 ± 0.86 6.50 ± 0.93 0.126 0.901Range 6 – 8 6 – 8
Radiotherapy No 13 (59.1%) 6 (75.0%) 0.639 0.424Yes 9 (40.9%) 2 (25.0%)
Interim CT Regressive 16 (72.7%) 2 (25.0%) 8.636 0.013Stationary 6 (27.3%) 4 (50.0%)Progressed 0 (0.0%) 2 (25.0%)
13/22 (59.1%) patients remained in remission till the end of the study follow-up duration and had a median DFS of 20months. Whereas 9/22 (40.9%) patients relapsed after a median DFS of 12 months. Eight/30 patients had a refractorydisease (26.7%) and a positive post-treatment PET/CT. The median DFS for all the studied patients was 25 months(95% CI 22.5 - 27.5) (Table 6, Figure 1).
Table 6: Disease-free survival of the study cohort (n=30)
Median Standard Error 95% Confidence IntervalLower Bound Upper Bound
DFS (months) 25 1.281 22.49 27.51
Figure1: Disease-free survival (n=30)
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The prognostic factors that significantly influenced the DFS were site of disease (p 0.017), presence or absence of Bsymptoms (p 0.017) and type of chemotherapy (p 0.045). The overall survival was 100% (Table 7, Figures 2, 3).
Table 7: Prognostic factors of disease-free survival
Count DFS (months) Log rank testMedian SE 95% Confidence Interval X2 P-value
PS 0 31 (19) 28 4.12 19.93 36.08 0.624 0.4292 (8) 21 4.08 13.00 29.00Comorbidities No 18 26 5.55 15.12 36.88 0.041 0.84Yes 12 24 2.84 18.44 29.56
Stage 1 4 29 3.00 23.12 34.88 2.42 0.492 9 24 1.49 21.08 26.923 11 21 2.39 16.32 25.684 6 30 0.00 0.00 0.00
Site of disease Nodal 19 24 1.56 20.94 27.06 8.111 0.017Extra- nodal 8 28 5.39 17.43 38.57Spleen 3 40 0.00 0.00 0.00A/B No symptoms 27 28 2.49 23.13 32.87 5.668 0.017Positive symptoms 3 15 0.00 0.00 0.00
Prognosis Low 3 23 4.90 13.40 32.60 4.53 0.104Low-Intermediate 15 29 0.74 27.55 30.45Intermediate-High 12 21 1.48 18.11 23.89Chemotherapy CHOP 22 28 3.10 21.93 34.07 3.685 0.045R-CHOP 8 19 3.00 13.12 24.88Radiotherapy No 19 28 3.01 22.09 33.91 0.369 0.544Yes 11 24 2.31 19.48 28.52
Interim CT Regressive 18 26 2.47 21.16 30.84 1.064 0.587Stationary 10 28 5.24 17.74 38.27Progressed 2 15 0.00 0.00 0.00
Salvage No 14 21 3.12 14.89 27.11 1.906 0.592ICE 8 29 0.82 27.40 30.60DHAP 5 23 0.00 0.00 0.00Others 3 0 0.00 0.00 0.00ICE: ifosfamide, carboplatin, etoposide, DHAP: dexamethasone, high dose Ara-C, platinol.
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Figure 2: Relation between chemotherapy and DFS Figure 3: Relation between disease site and DFSSalvage chemotherapy was indicated in relapsed patients 9/22 with negative PET imaging and all refractory PETpositive disease (p 0.106). Chemotherapy included ICE, DHAP, and other regimens in (26.7%, 16.6 %, and 10%)respectively. The number of chemotherapy cycles ranged from 3 to 6 cycles followed by PET/CT scan in only 9 patients(negative scan in 8 and positive in 1 patient). Only one patient with refractory disease required two cycles of secondline salvage chemotherapy ESHAP (etoposide, solu-medrol (methylprednisolone), high-dose Ara-C, platinol). Bonemarrow transplantation (BMT) was performed in all relapsed patients (Table 8).
Table 8: Salvage TreatmentPost-therapy PET Negative PET Positive PET Chi-square testNo = 22 No = 8 X² P-value
Salvage Chemotherapy No 13 (59.1%) 1 (12.5%) 6.118 0.106ICE 5 (22.7%) 3 (37.5%)DHAP 3 (13.6%) 2 (25.0%)Others 1 (4.5%) 2 (25.0%)Number of cycles Mean ± SD 3.00 ± 0.00 4.00 ± 1.67 1.593 0.139Range 3 - 4 2 - 6Follow up PET Negative PET 8 (36.4%) 1 (12.5%) 1.591 0.207Not done 14 (63.6%) 7 (87.5%)
Bone marrow transplantation Not done 14 (63.6%) 6 (75.0%) 0.341 0.559Done 8 (36.4%) 2 (25.0%)
4. DiscussionResponse evaluation after treatment of lymphomaserves as a measure of DFS and ORS as well as guidesdecisions whether to continue or change treatment asshown by many studies.34-39 The fundamentallimitations of CT are that identification of pathologiclymph nodes is based solely on size, while detection of
bone marrow and extra-nodal tissue involvement maybe limited. The integration of PET/CT allowed detectionof metabolic activity in non-enlarged lymph nodes aswell as high sensitivity to extranodal disease thusimproved initial disease staging. PET/CT has the abilityto distinguish between residual metabolically active
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tumor and necrosis or fibrosis which can be seen asresidual by contrast enhancement CT (CECT), so it isvery useful to assess end of treatment response.40 Alsosome studies compared CECT to 18 F-FDG PET/CT asregards detection of extranodal lymphoma, where thesensitivity and specificity were around 88% and 100%respectively for PET/CT vs. 50% sensitivity and 90%specificity for CECT.41,42 The use of PET for post-treatment response assessment in lymphoma bydistinguishing fibrosis or sclerosis from active residualdisease is perhaps the most established role of PET inlymphoma.43 FDG-PET/CT has a high PPV for remissionassessment. In FDG avid aggressive NHL includingDLBCL, the post-treatment PET has a high NPV 90 -100% and a lower PPV at 50 - 82%.14-16 The low PPVcould be due to the uptake of FDG by inflammationwhich could be seen after chemotherapy andradiotherapy. So to avoid equivocal results, thepost-therapy PET/CT imaging is performed 6 - 8 weeksafter the end of treatment20 or at least 3 weeks aftercompletion of chemotherapy and 8 -12 weeks afterradiation therapy.44 A systematic review of 19 studies byTerasawa et al.22 included 254 patients with aggressiveNHL; the authors observed that the sensitivity andspecificity of PET/CT in predicting relapse ranged from50 - 70% and 67 - 100%, respectively. Anothersystematic review by Zijlstra et al.18 included 15 studieswith 705 NHL patients; post-treatment PET had 72%and 100% sensitivity and specificity respectively fordetection of residual disease. Similarly, our resultsshowed that PET/CT had sensitivity of 75% andspecificity of 72.7% in predicting relapse. In agreementwith the literature, we demonstrated that PET/CT had alow PPV 50% and high NPV 88.9%. However, our resultsdisagree with that of Abo-Sheisha and Abdel Fattah45,they retrospectively studied 62 patients with DLBCLwho had CT documented residual masses aftercompletion of chemotherapy. The authors reported thatPET scan had higher sensitivity of 100%, a specificity of91%, a NPV of 100% and a PPV of 77.8%. Lavely et al.37similarly showed high post- therapy PET scanssensitivity of 100% and specificity of 84% for detectionof relapse in their study of 20 NHL patients. The PPV ofpost-treatment PET in the current study is close to thePPV of 78% reported by Juweid et al.26 while our NPVwas lower than NPV by the same authors (89% vs. 100%respectively). The sensitivity and specificity of PET/CThas been the subject of debate due to readers andtechnical aspects of the devices.25 While the clearest roleof PET scans in lymphoma is evaluation of response inthe end of treatment setting43, CT scan continues to bean important tool to confirm remission status aftertherapy whether as adjunct to PET or as a single imagingmodality in some practices.46Based on the ability of PET to better assess remission inaggressive more than in indolent NHL, the IHPincorporated FDG-PET/CT into the definitions ofpost-therapy responses.20 This led to better
discrimination of response categories where thecomplete response CR-unconfirmed category wasreplaced by complete or partial response based on FDGuptake.34 The shortcoming of the IHP in assessment ofresponse was that FDG avidity was defined relative tothe mediastinal blood pool. Subsequently the Deauvillecriteria were proposed for visually grading FDG PET/CTactivity in 2009 based on both mediastinal and liverblood pool.27 In 2014 the Lugano classification waspublished with the goal of simplification andstandardization of response assessment and reporting inlymphoma. It addresses the role of PET/CT for staging,interim and end of treatment response evaluation.30 Inthe FDG avid HL and aggressive NHL a negative end oftreatment FDG-PET scan excludes residual viable tumorwith high certainty, however, does not exclude thepresence of microscopic disease.37 When apost-treatment CT imaging shows a residual diseasemore than 2 cm despite a negative PET/CT, the risk ofmalignancy is higher.46Most of the available data on end-of-treatment PETscans in NHL were published in the pre-rituximab erawhere PET/CT at the end of therapy in aggressive NHLhad a high PPV and NPV. However, in the rituximab era,the incidence of false-positive PET scans seem to behigher making the PPV low and the NPV remains high.47Moskowitz et al.48 treated 98 patients with DLBCL usinga dose-dense R-CHOP-like regimen and interim PET/CTwere performed after four cycles. Biopsy of residualdisease as detected by positive interim PET scans wasdone, and it proved that 87% of patients had falsepositive residual disease. DFS of interimPET-positive/biopsy-negative patients was the same asthat in patients with a negative interim PET. The lowPPV of the PET scan detected in patients who receivedrituximab might be due to recruitment of immune cellsto the tumor by rituximab which is associated withinflammatory changes.48 Juweid et al.34 showed that in29 out of 54 patients who received rituximab, the end oftherapy PET had PPV of 68% and NPV of 80%. Han et
al.50 reported on 48 NHL patients who all receivedrituximab, they observed a low PPV of 19% in follow-upPETs performed for rituximab treated patients, whilethe NPV remained high at 85%. Avivi et al. 201351retrospectively studied 119 patients with newlydiagnosed DLBCL, 35 received CHOP and 84 receivedR-CHOP and the patients underwent 442 follow-upPETS. The patients were followed for a median of 3.4years, where 31 patients relapsed as detected by PETwith no false-negative results (17 vs. 14 respectively, p0.02). The authors compared the specificity and PPV ofPET scans which were significantly lower in patientsreceiving R-CHOP vs. CHOP (84% vs. 87%, p 0.023; 23%vs. 74%, p < 0.0001). This indicated a higherfalse-positive (FP) rate in subjects receiving R-CHOP(77% vs. 26%, p < 0.001) which remained as late as 3years following completion of treatment. The authorsconcluded that routine follow-up PET scans is not
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recommended in DLBCL patients treated with rituximaband also they recommended identifying strict criteria forperforming surveillance PET. In aggressive NHL changeof treatment should not be based on a positive PET scanduring or after rituximab-based therapy, it must be firstconfirmed by biopsy. Among the 30 patients we studied,22 received CHOP, and 8 received R-CHOP.End-of-therapy PET/CT was negative in 16/22 and 6/8of patients who were treated with CHOP and R-CHOPrespectively, and positive in 6/22 patients, 2/8 patientswho received CHOP and R-CHOP respectively (p 0.9).Studying the effect of rituximab on the results of post-therapy or follow-up PET scans was not one of the aimsof this study.PET scans can detect metabolic changes which precedechanges in tumor size; this enables to assess responseearlier during treatment.52 While end of therapy PET/CTin FDG- avid aggressive NHL such as DLBCL is a goodpredictor of outcome, the role of interim PET/CT is stillcontroversial because of its low PPV.22 Clinical trialsstudy the prognostic role of interim PET/CT aiming atoptimizing outcomes and reducing toxicity i.e.response-adapted therapy.53 Interim PET/CT is usuallyperformed after 2 - 4 cycles of the standard 6 cycleschemotherapy to identify patients who could benefitfrom earlier change in treatment.54 Still the role ofinterim PET/CT remains unclear, where some studiesfound that a negative interim PET/CT is associated witha better ORS and DFS.13 On the other hand, other studieshave not reported similar outcomes; partly due to use ofdifferent methods for analyzing the PET/CT scans.15,23,24Currently, changing treatment based on interim PET/CTresult is not recommended unless disease progression isdetected.23 Among the methods to improve the PPV ofinterim PET is the use of quantitative approaches likethe reduction of the maximum SUV in the ‘hottest’ lesionbefore and during treatment, known as ∆ SUV.55,56 In thistrial interim PET/CT was not done because of the highcost and limited finances. To date, the role of CT inlymphoma has been limited to assessing disease sites incombination with PET.Following first line therapy of lymphoma around30-50% of advanced HL and DLBCL relapse despite theimprovements in survival rates.57-59 Monitoring oflymphoma patients who achieved remission depends onclinical symptoms and signs for the earliest indication ofrecurrent disease in up to 80% of presentations.60Surveillance imaging is still widely done using CT scanswhen necessary.61 Follow-up PET/CT scans in patientswho are in remission have high false-positive rates62 andare not generally recommended. The PPV forsurveillance PET scans range from 21% to 74% foraggressive NHL.51,63-65 False positive scans can lead tounnecessary biopsies and patient anxiety. In ameta-analysis by Terasawa et al.41 the authorsdemonstrated that the sensitivity and specificity of PETin detecting relapse for HL were 50 - 100 and 67 - 100%respectively, while for NHL 33 - 77 and 82 - 100%,
respectively regardless of a residual mass on CT. Thelow PPV associated with surveillance PET scans limitstheir clinical benefit in detecting patients who wouldbenefit from more treatment.66,67 Han et al.50 observed alow PPV 19% in follow-up PETs of 38/48 DLBCLpatients treated with R-CHOP. El-Galaly et al.64 studied52 patients with aggressive NHL, including 43 patientswith DLBCL in whom PPV of surveillance NHL was 21%.The Lugano criteria recommend CT imaging forfollow-up as indicated by clinical signs and/orsymptoms. We followed the majority of patients in thisstudy using CT scans, PET/CT was performed in only9/30 patients which was negative in 8/9 of thesepatients. The high false positive rate of surveillance PETscans indicates the need for more refinement of theinterpretation criteria. CT had a similar low PPV 29%but at lower cost than PET/CT.63 However, in someselected relapsed cases PET/CT can be justified.64, 65Prognosis of patients with negative post-treatmentPET/CT is excellent compared to a positive scan. Saepen
et al.14 showed that 56 out of 67 NHL patients had anegative post- therapy PET/CT and remained incomplete remission at a median duration of 1.7 years,whereas all 26 with positive PET/CT relapsed at amedian of 2.4 months. In our study 22 out of 30 patientshad a negative end of treatment PET/CT, where 13patients remained in remission for the whole follow-upduration and 9 patients relapsed after a median DFS of12 months. As regards the factors affecting the result ofend of therapy PET/CT, our findings confirmed theknown prognostic factors of aggressive NHL affectingPET result and hence DFS, although not all reachedstatistical significance. In this study nodal versusextranodal disease, presence or absence of B symptoms,type of chemotherapy and IPI score were statisticallysignificant. Dabaja et al.46 studied 300 patientsdiagnosed with DLBCL; they confirmed the correlationof the known prognostic factors with the outcome inpatients with DLBCL including type of therapy, responseto therapy, and IPI score. Also they emphasized the roleof CT showing residual disease > 2 cm in PET/CTnegative patients, and recommended biopsy or closefollow-up of suspicious masses. Similarly, Abo-Sheishaand Abdel-Fattah45 showed many factors which affectedthe PET/CT result including stage of the disease, bonemarrow involvement, IPI score, performance status,residual mass > 1.5 cm (p 0.005).We acknowledge the shortcomings of our study. Theretrospective nature of the study may lead toinformation bias, since some data may be missing, thesubjectivity associated with reading PET scans, the verysmall number of patients and the short follow-upduration.
5. Conclusion
Volume 5 • Number 1 • 2017                                              International Journal of Cancer Therapy and Oncology 11
www.ijcto.org
© Ibrahim et al. ISSN 2330-4049
PET/CT scans have an established role in staging andassessment of response in aggressive NHL. Inaccordance with other studies we concluded that end-of- therapy PET/CT is a good predictor of DFS and ORSand helps to guide the need for further therapy.Relapsed patients had a significantly shorter DFSfollowing a positive scan than after a negative scan. CTcontinues to have an important role in post-treatmentresponse assessment whether as a single modality or incombination with PET scan. In Egypt, CT scan is morewidely available for post-treatment response evaluationof aggressive NHL and at lower cost. Ideally, the result ofthe PET/CT scans should be interpreted in amultidisciplinary setting depending on the clinicalsituation and the expected prognosis of the disease.
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